India: Compulsory Licensing For Three More Patented Cancer Drugs

Last Updated: 15 March 2013
Article by Mrinalini Gupta

Most Read Contributor in India, September 2016

The recent announcement of the Indian Government for granting Compulsory Licenses (CL) for three more patented drugs has been outrageously cheered by health activists and patients' across the country. The Department of Industrial Policy and Promotion (DIPP) is exploring a proposal from the Health Ministry to issue CL for three anti-cancer drugs.

The drugs which qualify the list are Roche's Herceptin (trastuzumab), a biotech drug for the treatment of breast cancer and Bristol-Myers Squibb's (BMS's) Sprycel (dasatinib) for the treatment of leukemia and Ixempra (ixabepilone) for the treatment of breast cancer.


1. Section 84

As per section 84(1) of the Patents (Amendment) Act, 2005 (hereinafter "the Act"), an application for the grant of CL on patent can be made to the Controller by any person interested on any of the following grounds:

  1. that the reasonable requirements of the public with respect to the patented invention have not been satisfied, or
  2. that the patented invention is not available to the public at a reasonably affordable price, or
  3. that the patented invention is not worked in the territory of India.1

However, this option can be explored only after the expiration of three years from the date of the grant of a patent. That is to say, if the Controller is satisfied that the aforesaid grounds exists, he may grant a CL upon such terms as he may deem fit.

2. Section 92

According to Section 92 of the Act, the CL on patent shall be granted by the Central Government any time after the sealing of the patent under following situations:

a circumstance of national emergency; or
a circumstance of extreme urgency; or
a case of public non-commercial use,

According to the Indian Express, Herceptin, Ixempra and Sprycel cost around 50,000 rupees (€687), 70,000- 80,000 rupees (€961 to €1,098) and 15,000 rupees (€206) respectively for a month's dosage2. Consequently these drugs are beyond the reach of the poor patients. As a result this situation gives rise to a case of public non-commercial use of the patent product. The Government is possibly exploring the choice of granting CL on patented drugs under the current section.

However, as per Section 92 (3) public health crises relates to Acquired Immuno Deficiency Syndrome, Human Immuno Deficiency Virus, tuberculosis, malaria and other epidemics. The point is, whether the uncontrolled growth of abnormal cells in the body leading to Cancer comes under the purview of the said section.


Section 100 of the Act confers power on the Central Government to use the invention for the purposes of government. The invention can be used by the Central Government or any person authorized in writing by it for purposes of government at any time after an application for a patent has been filed at the patent office or a patent has been granted.

For the purpose of Chapter XVII of the Act, an invention is said to be used for the purposes of Government if it is made, used, exercised or vended for the purposes of the Central Government, a State Government or a Government undertaking (Section 99)3.That is, the Government has the right to work that invention or use it or sell it using Government authorized channels.

3. Section 92A

This section facilitates the manufacture and export of patented pharmaceutical products to any country having insufficient or no manufacturing capacity in the pharmaceutical sector for the concerned product to address public health problems by granting CL for that patented pharmaceutical products.

The point to be noted is that the CL is granted solely for manufacture and the export of the concerned pharmaceutical product to such country.


Now, if the CL on patented drugs is granted in India the manufacturing of the biologically similar copies of the low cost generic versions of the drug would be another hurdle. It is easier to produce generic drugs that are pharmaceutically equivalent to innovative drugs. Whereas, manufacturing generic biologics (i.e. Biosimilars) which are complex protein molecules, biological in nature and similar to innovative biologics is comparatively difficult. It is not currently possible to demonstrate that two biologic drugs are pharmaceutically equivalent. The efficacy of biosimilar pharmaceuticals is highly dependent on the method of manufacture and formulation.

Apparently, minor and innocuous variations in manufacture and formulation can lead to unforeseen clinical consequences. For instance, in the case of biopharmaceutical 'Recombinant human erythropoietin (rHuEPO)' for the treatment for renal anemia the number of pure red-cell aplasia (PRCA) cases in patients treated with this medicine increased dramatically and the development of antibodies counteracting against it remained an obstacle for years to come.

Therefore, the generic biologics need to be pharmaceutically and therapeutically equivalent to the innovator drug and the companies manufacturing them have to be extra cautious as the biosimilars have the potential to induce an immunogenic response, rather than a therapeutic one.


This initiative of the Government to make the high-end medicines affordable to the common man is a welcoming step. The drugs Herceptin, Sprycel and Ixempra are way too expensive for the common man. Therefore the Government has taken a wise move to grant the CL on these drugs. The provision of CL under the Patents (Amendment) Act, 2005 is available as a remedy against abuse of patent right, not working of patent and to address the public health concern in India. Introduction of generic versions of pharmaceuticals through CL into the market is a way to reduce the health care costs. The crux is not that how long it will take to fix the predatory pricing of drugs by pharmaceutical giants but that the process has begun.





The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.